The U.S. Food and Drug Administration has approved Foundayo, a new oral GLP-1 medication for obesity developed by Eli Lilly, offering millions of Americans a pill-based option in a drug class previously dominated by injections. The approval marks a notable expansion of the GLP-1 market, which has rapidly reshaped how doctors and patients approach weight management.
Foundayo belongs to the same class of drugs as semaglutide — the active ingredient in Ozempic and Wegovy — but is taken orally rather than by injection. The development of an effective oral GLP-1 has been a closely watched goal in the pharmaceutical industry, as many patients have expressed reluctance or difficulty with injectable treatments.
The FDA granted the drug a speedy approval, a designation used to accelerate the review process for therapies that address serious conditions. FDA Commissioner Marty Makary was credited by some observers with facilitating the faster approval process, with The Hill noting he cited recent agency changes as enabling the quicker turnaround.
The approval is expected to intensify competition in the obesity drug market, where Novo Nordisk has held a dominant position with its injectable semaglutide products. Eli Lilly already markets the injectable GLP-1 drug tirzepatide under the brand name Zepbound, and Foundayo represents the company's push into the oral segment of the market.
Access and affordability questions are expected to follow the launch, as they have with other GLP-1 drugs. Injectable GLP-1 medications have faced coverage gaps, high out-of-pocket costs, and periodic shortages since their rise in popularity, and analysts expect similar scrutiny to accompany the rollout of Foundayo.
Left-Leaning Emphasis
- NPR and Vox focused on what the approval means for patients, including those who have avoided injections, and raised questions about affordability and insurance coverage.
- The Guardian framed the approval in the context of a rapidly growing and sometimes inequitable weight-loss drug market.
- Vox emphasized the broader public health implications and the science behind oral versus injectable GLP-1 delivery.
Right-Leaning Emphasis
- The Hill highlighted FDA Commissioner Marty Makary crediting recent FDA structural changes and staff reductions as factors that enabled the faster approval process.
- The Hill's framing positioned the speedy approval as a vindication of the current administration's approach to streamlining the FDA.